[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-349831-105":59,"doc-detail-349831-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","vaccine-safety-for-individuals-receiving-immune-checkpoint-inhibitor-therapy-a-narrative-review-of-current-literature-and-recommendations-for-future-research","Vaccine safety for individuals receiving immune checkpoint inhibitor therapy - A narrative review of current literature and recommendations for future research","","Vaccine safety for individuals receiving immune checkpoint inhibitor therapy is assessed through a narrative review of 28 primary research articles. Immune checkpoint inhibitors are widely used for many cancers and improve survival, but they are associated with immune-related adverse events that can involve any organ system and vary from mild to severe. Because vaccination has been hypothesized to increase risks, the review summarizes existing evidence and provides recommendations for future research. Current evidence indicates influenza and COVID-19 vaccines are safe for ICI-treated individuals and do not add risks beyond baseline ICI therapy risk.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/vaccine-safety-for-individuals-receiving-immune-checkpoint-inhibitor-therapy-a-narrative-review-of-current-literature-and-recommendations-for-future-research/349831/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/vaccine-safety-for-individuals-receiving-immune-checkpoint-inhibitor-therapy-a-narrative-review-of-current-literature-and-recommendations-for-future-research/349831.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why might vaccination be a concern for people receiving immune checkpoint inhibitors?","Question",{"text":112,"@type":113},"Immune checkpoint inhibitors can cause immune-related adverse events affecting any organ system. It has been hypothesized that vaccination could increase the risk of these immune-related adverse events or other vaccine-associated adverse events.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What do existing studies suggest about influenza and COVID-19 vaccine safety for ICI-treated individuals?",{"text":117,"@type":113},"The review states that influenza and COVID-19 vaccines are safe for individuals receiving immune checkpoint inhibitor therapy and do not pose additional risks of immune-related adverse events beyond baseline risks associated with ICI therapy.",{"name":119,"@type":110,"acceptedAnswer":120},"How soon after starting immune checkpoint inhibitor therapy do immune-related adverse events tend to occur?",{"text":121,"@type":113},"The review notes that immune-related adverse events are more common in the 2–4 weeks after ICI initiation, and the risk attenuates over time, though events may also occur more than 20 weeks after administration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},349831,1790633567,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","REVIEW  \nVaccine safety for individuals receiving immune checkpoint inhibitor therapy: A narrative review of current literature and recommendations for future research  \nMaria E. Sundaram   \nCenter for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, Marshfield, WI, USA  \nABSTRACT  \nSome individuals with cancer may receive immunomodulatory treatment such as immune checkpoint inhibitors (ICIs) . ICIs are now part of standard of care for many cancers and have improved survival for cancer patients. However, they are also associated with immune-related adverse events (irAEs), which can affect any organ or system, and can range from mild to severe. It has been hypothesized that vaccination of these individuals could increase the risk of irAEs or other vaccine-associated adverse events. This narrative review of 28 primary research articles presents findings from existing literature on vaccine safety for individuals receiving ICIs, and makes recommendations for future research on this topic. The existing evidence suggests that influenza and COVID-19 vaccines are safe for individuals receiving ICIs and do not pose additional risks of irAEs beyond baseline risks associated with ICI therapy.  \nARTICLE HISTORY  \nReceived 27 June 2025 Revised 10 December 2025 Accepted 17 December 2025  \nKEYWORDS  \nImmune checkpoint inhibitor; vaccine; safety; cancer therapy  \nIntroduction  \nCancer patients are at increased risk for infection-related severe outcomes, caused by influenza, COVID-19, respiratory syncytial virus (RSV), and pneumococcal disease.1,2 Vaccines play an important role in the prevention of these diseases, especially for cancer patients and other similar high-risk populations.3 Asa result, cancer patients are recommended to receive seasonal vaccines and age-and risk-based vaccines, including influenza and COVID-19 vaccines.1  \nSome individuals receiving treatment for cancer may receive immunomodulatory treatments, such as immune checkpoint inhibitor (ICI) therapy. ICIs work by releasing a “brake” on T cell function, which allows for greater T cell-mediated action against cancer cells.4–6 There are several classes of ICIs that serve this purpose, including programmed cell death protein 1 (PD-1) inhibitors, PD-1 ligand 1 (PD-L1) inhibitors, and cytotoxic T lymphocyte associated protein 4 (CTLA-4) inhibitors5,7 (Table 1) . There is an additional class of ICI called lymphocyte activation gene 3 (LAG-3) inhibitor; currently, there is one LAG-3 inhibitor which is administered with a PD-1 inhibitor as a combination therapy.10, 11  \nICIs have been approved for use in treating a wide range of cancers with substantial positive impact,5, 12–14 especially non-small-cell lung cancer (NSCLC)15 and melanoma.16 Use of ICIs, either via monotherapy or combined therapy (with multiple ICI types or alongside cytotoxic chemotherapy), has increased rapidly over the past decade.6  \nImmune-related adverse events in individuals on ICI therapy  \nBecause the primary mechanism of ICIs results in increased immune system reactivity, ICIs carry a risk of immune-related adverse events (irAEs) .4 ,6 These events can affect any organ or organ system, though outcomes involving GI, dermatologic, hepatic, endocrine, and pulmonary systems  \nCONTACT Maria E. Sundaram, MSPH, PhD  [sundaram.maria@marshfieldresearch.org](sundaram.maria@marshfieldresearch.org)  Center for Clinical Epidemiology and Population Health, Marshfield Clinic Research Institute, 1000 N. Oak Ave., Marshfield, WI 54449, USA.  \n Supplemental data for this article can be accessed online at [https://doi.org/10.1080/21645515.2025.2607893](https://doi.org/10.1080/21645515.2025.2607893) .  \n© 2026 The Author(s) . Published with license by Taylor & Francis Group, LLC.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License ([http://creativecommons.org/licenses/by-nc/4.0/](http://creativecommons.org/licenses/by-nc/4.0","cbCaieRWTxFQw7bM","https://ap.wps.com/l/cbCaieRWTxFQw7bM","pdf",483166,17,"English","# Introduction\n## Immune-related adverse events in individuals on ICI therapy\n# Vaccine safety evidence and implications\n## Recommendations for future research","[{\"question\":\"Why might vaccination be a concern for people receiving immune checkpoint inhibitors?\",\"answer\":\"Immune checkpoint inhibitors can cause immune-related adverse events affecting any organ system. It has been hypothesized that vaccination could increase the risk of these immune-related adverse events or other vaccine-associated adverse events.\"},{\"question\":\"What do existing studies suggest about influenza and COVID-19 vaccine safety for ICI-treated individuals?\",\"answer\":\"The review states that influenza and COVID-19 vaccines are safe for individuals receiving immune checkpoint inhibitor therapy and do not pose additional risks of immune-related adverse events beyond baseline risks associated with ICI therapy.\"},{\"question\":\"How soon after starting immune checkpoint inhibitor therapy do immune-related adverse events tend to occur?\",\"answer\":\"The review notes that immune-related adverse events are more common in the 2–4 weeks after ICI initiation, and the risk attenuates over time, though events may also occur more than 20 weeks after administration.\"}]","Vaccine safety for individuals receiving immune checkpoint inhibitor therapy - A narrative review of current literature and recommendations for future research | PDF",1790085864,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/82f7de401f7f6c9bfc542a70a7def929.webp",983,1310,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11bd9f9f17563448318f1a3bca436bb3.webp",982,1309,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa4dbd490fd79c98a1faaa9e972a0ce9.webp",981,1308,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3a23406fb95b062cae52930a8aeef408.webp",980,1306]